Micro-Invasive Glaucoma Surgery (MIGS)
The treatment for glaucoma has come a long way. Today’s advanced technologies and procedures make it possible to diagnose and successfully manage this progressive disease. And while the overall goal of treatment has always remained the same — reducing intraocular pressure (IOP) and glaucomatous progression — Micro-Invasive Glaucoma Surgery (MIGS) is quickly becoming a widely-accepted approach for lowering eye pressure in mild-to-moderate open-angle glaucoma. 1
Glaucoma Therapy Advances
Glaucoma is primarily managed with prescription eye drops. If a patient’s glaucoma progresses or the patient stops responding to the eye drops, a surgical solution is offered. These surgical solutions are often highly invasive, require long recovery times, and could result in long-term complications.
As technology has progressed, less invasive techniques have emerged that have improved the safety profile for glaucoma surgery. This has opened more surgical options for patients interested in effective glaucoma management that does not rely solely on the continuous use of prescription medication.
A Revolution in Glaucoma Therapy
With the development of trabecular micro-bypass technologies, such as iStent inject®, Micro-Invasive Glaucoma Surgery (MIGS) has become the preferred approach to glaucoma management for many eye doctors and their patients with open-angle glaucoma.
Performed at the time of cataract eye surgery or as a stand-alone procedure, iStent inject® has proved to be effective in decreasing IOP, with an excellent safety profile, few complications, and fast recovery time. 2
iStent inject® may also reduce patients’ need for medications as determined by an eye doctor. The majority of patients who received iStent inject® in the European-based Synergy Study remained medication-free at 12 months.2 Other benefits associated with this innovative treatment include:
• Minimally traumatic to delicate eye tissue
• Effectively lowers IOP
• Excellent safety profile
• Rapid recovery
1. Marketscope 2015
2.Voskanyan L, García-Feijoó J, Belda J, Fea A, Jünemann A, Baudouin C. Prospective, Unmasked Evaluation of the iStent inject System for Open-Angle Glaucoma: Synergy Trial. Adv Ther 2014;31:189-201.
Find out more about iStent inject®
Help is right around the corner. Leading ophthalmologists in the United Kingdom offer iStent inject® as part of their treatment for glaucoma. You can enquire if you are a suitable candidate for iStent inject® by contacting an ophthalmologist near you.